RxDoctor Payments Data

Christopher Crooker, MD

Internal Medicine · Lawrenceville, GANPI 1609801018

Payments from drug & device makers

$19,184in general payments, 2019–2025

Across 1,207 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Pfizer$955
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$19,101100%
  • Education$830%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk161$2,050
Amgen(2 entities)112$1,899
AbbVie(2 entities)143$1,791
Lilly USA, LLC74$1,175
AstraZeneca(2 entities)51$1,043
Pfizer64$955
Amarin Pharma, Inc.48$681
GSK38$680
Otsuka America Pharmaceutical, Inc.31$596
Johnson & Johnson33$556
Astellas Pharma US Inc27$538
Boehringer Ingelheim29$486
Sanofi-aventis U.S. LLC26$484
Sumitomo Pharma America, Inc.42$469
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$461
Esperion Therapeutics, Inc.23$406
Takeda Pharmaceuticals U.S.A., Inc.21$335
Teva Pharmaceuticals USA, Inc.23$295
Paratek Pharmaceuticals, Inc.15$263
Corium, LLC9$258
Biohaven Pharmaceuticals, Inc.13$235
Shield Therapeutics Inc4$223
Lundbeck LLC8$177
Biohaven Pharmaceutical Holding Company Ltd.9$176
Abbott9$163
Eisai Inc.9$162
Supernus Pharmaceuticals, Inc.8$153
Novartis9$134
Bayer6$129
Arbor Pharmaceuticals, Inc.8$116
Upsher-smith Laboratories LLC7$111
Daiichi Sankyo Inc.5$95
IBSA Pharma Inc.6$94
Inspire Medical Systems, Inc.5$91
Verity Pharmaceuticals Inc.4$89
Merck6$86
Scilex Pharmaceuticals Inc.4$84
Avanir Pharmaceuticals, Inc.5$81
Xeris Pharmaceuticals, Inc.4$76
Biogen4$75
Jazz Pharmaceuticals Inc.5$74
Neos Therapeutics, LP5$74
Amneal Pharmaceuticals LLC4$68
Kowa Pharmaceuticals America, Inc.5$67
Azurity Pharmaceuticals, Inc.3$65
Dexcom, Inc.3$63
Nalpropion Pharmaceuticals LLC3$58
Exact Sciences3$55
Noven Therapeutics, LLC3$54
Mylan Specialty L.p.3$51
Antares Pharma, Inc.3$51
Ironshore Pharmaceuticals Inc.3$50
Phathom Pharmaceuticals, Inc.7$47
Eyevance Pharmaceuticals LLC2$39
Hikma Pharmaceuticals USA2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$33
Aytu Biopharma, Inc.2$30
Nabriva Therapeutics, PLC2$30
Medtronic2$27
Currax Pharmaceuticals LLC2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,184 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$177,690
Medicare patients
924
Services billed
3,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide301$337,761
EliquisApixaban198$203,529
MounjaroTirzepatide107$118,433
JanuviaSitagliptin Phosphate100$115,841
JardianceEmpagliflozin103$110,748
MyrbetriqMirabegron99$73,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$53,803
TrulicityDulaglutide39$50,133
FarxigaDapagliflozin Propanediol64$48,630
ProliaDenosumab28$48,494
XareltoRivaroxaban42$41,454
LinzessLinaclotide41$34,935
GemtesaVibegron37$21,835
Repatha SureclickEvolocumab23$20,249
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$20,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$2,050$356,159313 claims
PfizerEliquis, Lyrica$955$217,835220 claims
Lilly USA, LLCMounjaro, Trulicity$1,175$168,566146 claims
MerckJanuvia, Janumet$86$134,936114 claims
Boehringer IngelheimJardiance, Combivent Respimat$486$117,407117 claims
AstraZenecaFarxiga, Nexium, Symbicort$1,043$75,584105 claims
Astellas Pharma US IncMyrbetriq$538$73,40899 claims
GSKTrelegy Ellipta, Breo Ellipta$680$61,04274 claims
AbbVieLinzess, Synthroid$1,791$50,907234 claims
AmgenProlia$1,899$48,49428 claims
Johnson & JohnsonXarelto$556$41,45442 claims
Sumitomo Pharma America, Inc.Gemtesa$469$21,83537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →